Akero Therapeutics (AKRO) Competitors $30.64 -0.39 (-1.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AKRO vs. ALBO, CBAY, ENTA, ROIV, ASND, LEGN, ELAN, CYTK, BPMC, and NUVLShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Albireo Pharma (ALBO), CymaBay Therapeutics (CBAY), Enanta Pharmaceuticals (ENTA), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry. Akero Therapeutics vs. Albireo Pharma CymaBay Therapeutics Enanta Pharmaceuticals Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Cytokinetics Blueprint Medicines Nuvalent Albireo Pharma (NASDAQ:ALBO) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Which has more risk and volatility, ALBO or AKRO? Albireo Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Does the MarketBeat Community favor ALBO or AKRO? Albireo Pharma received 190 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 63.53% of users gave Akero Therapeutics an outperform vote while only 54.28% of users gave Albireo Pharma an outperform vote. CompanyUnderperformOutperformAlbireo PharmaOutperform Votes29854.28% Underperform Votes25145.72% Akero TherapeuticsOutperform Votes10863.53% Underperform Votes6236.47% Do institutionals & insiders hold more shares of ALBO or AKRO? 94.3% of Albireo Pharma shares are owned by institutional investors. 6.9% of Albireo Pharma shares are owned by insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ALBO or AKRO? Akero Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 52.88%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Albireo Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Albireo Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akero Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is ALBO or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Albireo Pharma's net margin of -228.51%. Akero Therapeutics' return on equity of -32.46% beat Albireo Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Albireo Pharma-228.51% -97.13% -46.89% Akero Therapeutics N/A -32.46%-29.83% Which has higher earnings & valuation, ALBO or AKRO? Albireo Pharma has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlbireo Pharma$40.58M22.52-$34.03M-$6.72-6.57Akero TherapeuticsN/AN/A-$151.76M-$3.75-8.17 Does the media prefer ALBO or AKRO? In the previous week, Akero Therapeutics had 23 more articles in the media than Albireo Pharma. MarketBeat recorded 23 mentions for Akero Therapeutics and 0 mentions for Albireo Pharma. Akero Therapeutics' average media sentiment score of 0.33 beat Albireo Pharma's score of 0.20 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Albireo Pharma Neutral Akero Therapeutics Neutral SummaryAkero Therapeutics beats Albireo Pharma on 11 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-8.1710.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book3.195.474.674.68Net Income-$151.76M$153.61M$119.07M$226.08M7 Day Performance2.94%-2.00%-1.83%-1.04%1 Month Performance-0.86%-7.47%-3.62%1.04%1 Year Performance90.63%31.80%31.63%26.28% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics4.0502 of 5 stars$30.64-1.3%$46.83+52.9%+83.8%$2.17BN/A-8.1730Analyst ForecastInsider TradeALBOAlbireo PharmaN/A$44.15-0.2%N/A+0.0%$913.91M$40.58M-6.57130Analyst ForecastCBAYCymaBay Therapeutics0.8741 of 5 stars$32.48flat$32.50+0.1%+74.1%$3.73B$31.07M-33.48101Analyst ForecastENTAEnanta Pharmaceuticals2.9547 of 5 stars$9.08-3.6%$20.00+120.3%+1.6%$199.60M$79.20M-1.67145ROIVRoivant Sciences3.2845 of 5 stars$11.49+1.6%$17.93+56.0%+30.6%$8.36B$124.79M2.03860ASNDAscendis Pharma A/S3.0066 of 5 stars$124.380.0%$191.77+54.2%+32.7%$7.55B$288.08M0.00640Analyst UpgradeLEGNLegend Biotech1.7671 of 5 stars$40.14+4.5%$81.46+102.9%-33.7%$7.00B$285.14M0.001,800Analyst RevisionELANElanco Animal Health4.1102 of 5 stars$13.44+1.0%$17.14+27.6%+13.1%$6.58B$4.42B33.609,300CYTKCytokinetics4.025 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$6.03B$7.53M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageBPMCBlueprint Medicines2.713 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.01B$249.38M0.00640Analyst ForecastAnalyst RevisionNUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040 Related Companies and Tools Related Companies Albireo Pharma Alternatives CymaBay Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKRO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts